2020

Dutch institutions failing to register results of clinical trials

HAI Releases Annual Report 2019

Why TRIPS flexibilities are a crucial mechanism for access to medicines

EU Must Not Miss its Chance on WHO Technology Pool

TRIPS-flexibilities in Health Crises and Beyond

To tackle COVID-19 pandemic, transparency and collaboration are vital

Ensure transparency, affordability and availability of vaccines and treatments for COVID-19, say MEPs

HAI Follows Dutch Government Advice in Response to COVID-19

Europe’s Beating Cancer Plan

Niets magisch aan medicijnprijzen

Nothing magical about medicine prices

US puts pressure on the Netherlands over compulsory licenses

A busy week at the Court of Justice of the European Union

2019

How to measure change in EU Policy

Health Technology Assessments: will 2020 end the deadlock?

Is clinical trial transparency under threat?

REBRAND: Fact or Fiction publication

An insightful day at the EURIPID stakeholder meeting in Budapest

A Momentous Week for Access to Medicines

Dr Marg Ewen Receives the Helen Clark-JoPPP Award

No Universal Health Coverage without Universal Medicines Coverage

2018

A Year at the Heart of Regulatory Decision Making

Staff Spotlight: Jaume Vidal

Time for a Treaty? ReAct Reports on Second Consultation on Global Development & Stewardship Framework to Combat AMR

Medicijnen: de link met de maatschappij

What Role Can Civil Society Play in the European Regulatory Process?

Open Science for Health: Shaping the New Framework Programme

2017

EU-Mercosur Trade Agreement: A bad deal for transparency, policy coherence and access to medicines

New Dutch Government Must Ensure Transparency to Control Medicine Prices

Staff Spotlight: Tim Reed